Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
| Autor: | Vishwa B Patel, Iqra Nawaz, Jaydeep Mahasamudram, Minu C Abraham, Faryal Altaf, Mohamed Farag, Sameer D Kandhi, Nismat Javed, Harish Patel, Haider Ghazanfar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
exenatide glucagon-like peptide-1 receptor agonist 030204 cardiovascular system & hematology Chronic liver disease 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine Medicine nonalcoholic steatohepatitis Glucagon-like peptide 1 receptor liraglutide semaglutide business.industry Liraglutide pathogenesis Semaglutide fibrosis Fatty liver Endocrinology/Diabetes/Metabolism Gastroenterology General Engineering non-alcoholic fatty liver disease medicine.disease Endocrinology Steatosis Steatohepatitis business Exenatide 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the lethal causes of chronic liver disease globally. NAFLD can ultimately progress to non-alcoholic steatohepatitis (NASH) given persistent cellular insult. The crux of the problem lies in fat accumulation in the liver, such as increased fatty acid substrates owing to consumption of a high-fat diet, altered gut physiology, and excess adipose tissue. Being the hepatic manifestation of metabolic syndrome, insulin resistance is also among one of the many stimuli. Therefore, drugs, such as glucagon-like peptide-1 receptor agonist (GLP-1 RA) can play a significant role in reducing inflammation, in addition to weight loss and dietary habits. In this review article, we have reviewed the role of exenatide, liraglutide, and semaglutide in the management of NASH. Two of the agents, exenatide and semaglutide, have a predominant role in reducing alanine aminotransferase (ALT) levels, therefore reducing inflammation and promoting weight loss. However, these agents have a lesser impact on the degree of fibrosis. Liraglutide, on the other hand, has been shown to significantly decrease the degree of fibrosis and has been found helpful in reversing mild degrees of steatosis. Therefore, these agents warrant attention to the new perspective that has been presented so that future guidelines may incorporate and streamline individualized therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|